News

Show
news from

Quell Therapeutics Significantly Expands Clinical Manufacturing Capacity for its Engineered Treg Cell Therapies through a Collaboration with the Cell and Gene Therapy Catapult

Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK

Autolus Therapeutics announces the appointment of John H. Johnson as non-executive chairman of its Board of Directors

Neogene Therapeutics Appoints Han Lee, Ph.D., MBA, as Chief Financial Officer

Autolus Therapeutics announces publication of obe-cel (AUTO1) Phase 1 ALLCAR19 data in adults with relapsed/ refractory B-ALL in Journal of Clinical Oncology

Achilles Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights

Load more

Search